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SUMMARY
Mutations in the juxtamembrane and kinase domains of FLT3 are common in AML, but it is not known
whether alterations outside these regions contribute to leukemogenesis. We used a high-throughput
platform to interrogate the entire FLT3 coding sequence in AML patients without known FLT3 muta-
tions and experimentally tested the consequences of each candidate leukemogenic allele. This
approach identified gain-of-function mutations that activated downstream signaling and conferred
sensitivity to FLT3 inhibition and alleles that were not associated with kinase activation, including
mutations in the catalytic domain. These findings support the concept that acquired mutations in
cancer may not contribute to malignant transformation and underscore the importance of functional
studies to distinguish ‘‘driver’’ mutations underlying tumorigenesis from biologically neutral ‘‘passen-
ger’’ alterations.INTRODUCTION
The receptor tyrosine kinase (TK) FLT3 and its cognate
ligand are important for the expansion of early hematopoi-Caetic progenitor cells and for the generation of mature nat-
ural killer cells and dendritic cells. Binding of FLT3 ligand
to the extracellular (EC) domain of FLT3 induces recep-
tor dimerization, which promotes phosphorylation of theSIGNIFICANCE
High-throughput DNA sequencing has provided insights into the mutational profiles of human cancers and repre-
sents a promising strategy for the identification of therapeutic targets. However, recognizing the subset of func-
tionally relevant mutations has proven difficult. We used a combined genetic and functional approach to evaluate
a series of candidate mutations in the receptor tyrosine kinase FLT3 that were identified in patients with AML. This
strategy enabled distinction between activating alleles that conferred sensitivity to a small-molecule inhibitor and
bystander mutations that did not result in kinase activation. Remarkably, these latter alterations included muta-
tions in key functional domains of FLT3. These results emphasize that complementary functional studies are crit-
ical for validation of suspected oncogenic alleles from large-scale genomic screens.ncer Cell 12, 501–513, December 2007 ª2007 Elsevier Inc. 501
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Driver and Passenger Mutations of FLT3 in AMLFLT3 kinase domain, thereby activating the receptor and
several downstream signaling pathways, primarily the
PI3K/AKT pathway and the RAS/RAF/MEK/ERK cascade
(Parcells et al., 2006).
In patients with acute myeloid leukemia (AML), somatic
mutations that result in constitutive activation of FLT3
have been identified in two functional domains of the
receptor, the juxtamembrane (JM) domain and the kinase
domain. The JM domain, which has been shown to be crit-
ical for kinase autoinhibition (Griffith et al., 2004), is disrup-
ted by internal tandem duplications (ITDs) in 25%–30% of
adult AML patients (Stirewalt and Radich, 2003), whereas
JM domain point mutations have been described in
approximately 1% of cases (Reindl et al., 2006; Stirewalt
et al., 2004). FLT3 ITDs induce constitutive phosphoryla-
tion of several signal transduction intermediates, including
STAT5, AKT, and ERK1/2 (Parcells et al., 2006) and cause
myeloproliferative disease in various murine models (Kelly
et al., 2002; Lee et al., 2005). JM domain point mutations
also result in constitutive activation of STAT5 and AKT
(Reindl et al., 2006), but their in vivo transforming potential
has not been studied.
The activation loop (AL) in the carboxy-terminal lobe of
the kinase domain is affected by point mutations, inser-
tions, or deletions in approximately 7% of AML cases
(Frohling et al., 2005). AL mutations share several signal
transduction properties with FLT3 ITDs, for example, con-
stitutive phosphorylation of AKT and ERK1/2 (Choudhary
et al., 2005; Spiekermann et al., 2003). However, substantial
differences between the two mutation types in the activation
of STAT5 have been observed in some studies (Choudhary
et al., 2005; Grundler et al., 2005; Rocnik et al., 2006), but
not in others (Bagrintseva et al., 2004; Grundler et al.,
2003; Spiekermann et al., 2003), and mice transplanted
with BM expressing FLT3 AL mutations do not develop
myeloid disease but rather, a T cell lymphoproliferative
disorder with longer latency (Grundler et al., 2005). A mu-
tation in the amino-terminal lobe of the kinase domain was
found to induce constitutive activation of AKT, ERK1/2,
and STAT5 (Schittenhelm et al., 2006).
From a clinical perspective, FLT3 mutations are impor-
tant as a result of their prognostic relevance and because
constitutively activated FLT3 is an attractive therapeutic
target. FLT3 ITDs are associated with an increased risk
of relapse and short survival (Yanada et al., 2005), and
patients with low or absent levels of wild-type (WT) FLT3
appear to have a particularly dismal outcome (Thiede
et al., 2002; Whitman et al., 2001). In contrast, the prog-
nostic relevance of FLT3 AL mutations remains controver-
sial despite several studies on large patient series (Yanada
et al., 2005). Currently, there are four selective FLT3 inhib-
itors at various stages of clinical development, including
PKC412 (midostaurin), CEP-701 (lestaurtinib), MLN518
(tandutinib), and SU11248 (sunitinib) (Knapper, 2007).
These compounds are well tolerated at doses that achieve
inhibition of FLT3 and have shown moderate activity in
relapsed or refractory AML patients with activating FLT3
mutations. In addition, some patients without FLT3 ITDs
or known AL mutations have responded to FLT3 inhibitors,502 Cancer Cell 12, 501–513, December 2007 ª2007 Elsevier Isuggesting the possibility of other mutations that result in
constitutive activation of FLT3. Ongoing clinical trials are
evaluating the use of FLT3 inhibitors in combination with
chemotherapy.
Previous studies have focused on the detection of mu-
tations in the JM and kinase domains of FLT3, whereas the
frequency and spectrum of sequence alterations outside
these regions have not been systematically studied. We
therefore performed high-throughput DNA sequencing of
all coding exons of FLT3 in AML patients without FLT3
ITDs or known AL mutations. The primary aim of such a ge-
nomic screen is to identify ‘‘driver’’ mutations that are
causally implicated in cancer development. However, re-
cent large-scale sequencing studies in solid tumors that
used statistical approaches to evaluate the impact of
DNA sequence variants have demonstrated the difficulties
in distinguishing driver mutations from ‘‘passenger’’ alter-
ations that confer no clonal growth advantage (Forrest and
Cavet, 2007; Getz et al., 2007; Greenman et al., 2007; Ru-
bin and Green, 2007; Sjoblom et al., 2006; Wood et al.,
2007). To address this problem, we experimentally tested
the consequences of each candidate oncogenic allele
identified in our mutation screen. This combined genetic
and functional approach successfully identified gain-of-
function mutations in the EC domain, the JM domain,
and the AL of FLT3 and several passenger alterations
that did not result in constitutive kinase activity. Further-
more, we investigated the structural implications, signal
transduction properties, and sensitivity to FLT3 inhibition
of the activating alleles.
RESULTS
High-Throughput DNA Sequence Analysis of FLT3
We performed bidirectional sequencing of all FLT3 coding
exons in pretreatment samples from 222 adult AML pa-
tients without known activating mutations of FLT3, KIT,
and NRAS. Sequence data were evaluated for quality
and coverage within the region of interest of each exon
that included all coding bases and the five flanking intronic
bases at the 50 and 30 ends. High-quality, bidirectional
sequence reads were obtained for more than 90% of all
samples analyzed (see Table S1 in the Supplemental
Data available with this article online).
FLT3 Sequence Variants in Patients with AML
We identified a total of 17 heterozygous nucleotide
changes. Five of these changes corresponded to germline
variants listed in single-nucleotide polymorphism (SNP)
databases. Of the remaining 12 sequence alterations, 9
were predicted to change the amino acid sequence
of FLT3 (nonsynonymous substitutions; Table 1 and
Figure S1), whereas 3 were annotated as synonymous
substitutions, resulting in a ratio of nonsynonymous to
synonymous mutations of 3.
The nine nonsynonymous sequence variants that were
not known SNPs have not been observed in 48 normal
control samples in which the entire coding region of
FLT3 had previously been sequenced (Ley et al., 2003)nc.
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a mutation screen of all protein kinase genes in 210 human
cancers (Greenman et al., 2007). These alterations were,
Table 1. Nonsynonymous Sequence Variants Identified
by High-Throughput Sequencing of FLT3 in 222 AML
Patients
DNA Exon Protein Domain
581A > G 5 T167A extracellular
662G > A 5 V194M extracellular
1052G > A 8 D324N extracellular
1172T > C 9 Y364H extracellular
1434C > T 11 S451F extracellular
1751G > A 13 V557I transmembrane
1797A > G 14 Y572C juxtamembrane
1857T > G 14 V592G juxtamembrane
2293G > C 18 M737I kinase
2574G > A 20 G831E activation loop
2583G > A 20 R834Q activation loop
Sequence numbering is according to Ensembl Transcript/
Peptide ID ENST00000241453. D324N (refSNP ID
rs35602083) and V557I (refSNP ID rs35958982) are known
germline polymorphisms. Different mutations involving amino
acids V592 and R834 (V592A, R834_D835 del, R834_D835in-
sALG) are reported in the COSMIC database (version 30;
http://www.sanger.ac.uk/genetics/CGP/cosmic/).Canctherefore, considered to be candidate leukemogenic mu-
tations that warrant experimental validation. Paired diag-
nostic and remission material was available from a patient
with an M737I substitution in the FLT3 kinase domain. This
variant was present at diagnosis but not in the remission
sample, demonstrating that it was somatically acquired
(Figure S1). The three synonymous sequence variants
that were not known SNPs were considered to be non-
functional and were, therefore, not further investigated.
FLT3 S451F, Y572C, V592G, and R834Q Are
Gain-of-Function Mutations that Induce
Constitutive Kinase Activation
To determine the functional consequences of all nine
candidate mutations, we tested their ability to transform
murine hematopoietic BaF3 cells to cytokine-independent
growth, a property conferred by a broad spectrum of on-
cogenic TK alleles. Cells expressing S451F in the EC do-
main, Y572C or V592G in the JM domain, and R834Q in
the AL were able to grow in the absence of interleukin-3
(IL-3; Figure 1A). Immunoprecipitation of FLT3 followed
by western blotting with a phosphotyrosine-specific anti-
body demonstrated that these mutant kinases induced
constitutive phosphorylation of FLT3 (Figure 1B). These
results indicate that the S451F, Y572C, V592G, and
R834Q alleles are gain-of-function mutations that result
in constitutive kinase activation. To perform a rapid and
inexpensive secondary screen for these mutations, we
designed allele-specific primer extension assays and per-
formed genotype determination in an independent cohortFigure 1. Constitutive Kinase Activation by FLT3 S451F, Y572C, V592G, and R834Q
(A) Expression of FLT3 S451F, Y572C, V592G, and R834Q resulted in IL-3-independent growth of BaF3 cells. Cells expressing the known AL mutation
D835Y were used as positive control. Cells expressing WT FLT3 were used as negative control. Experiments were performed in triplicate. Values are
represented as mean ± SEM.
(B) Expression of FLT3 S451F, Y572C, V592G, and R834Q in BaF3 cells resulted in constitutive FLT3 autophosphorylation. Cells were maintained in
IL-3-free medium for 6 hr, FLT3 was immunoprecipitated from whole-cell lysates, and immunoprecipitates were analyzed by western blotting with an
anti-phosphotyrosine antibody. Cells expressing a FLT3 ITD mutation (W51) or FLT3 D835Y were used as positive controls. Cells expressing WT FLT3
or the nontransforming G831E allele were used as negative controls.
(C) Expression of FLT3 T167A, V194M, Y364H, M737I, and G831E did not result in IL-3-independent growth of BaF3 cells. Experiments were per-
formed in triplicate. Values are represented as mean ± SEM.er Cell 12, 501–513, December 2007 ª2007 Elsevier Inc. 503
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tional case positive for the S451F substitution and one
additional case with the R834Q allele. Thus, the overall
prevalence of activating FLT3 mutations in this study
was 1.7% (6 of 349 cases).
Cells expressing any of the remaining five nonsynony-
mous sequence variants in the EC domain, the kinase
domain, and the AL underwent apoptosis when cultured
in the absence of exogenous cytokines, and constitutive
phosphorylation of FLT3 was not observed (Figures 1B
and 1C). These results indicate that a substantial propor-
tion of the nonsynonymous sequence variants detected in
FLT3 are likely to be passenger mutations. To increase
confidence that the four presumed passenger mutations
for which no matched normal DNA sample was available
(T167A, V194M, Y364H, and G831E) did not represent
germline polymorphisms or sequence artifacts, the follow-
ing steps were taken. First, we sequenced the corre-
sponding exons of FLT3 in 102 normal DNA samples
and detected no abnormalities. Second, we determined
by mass spectrometry genotyping that the G831E allele
in the FLT3 AL was not present in the panel of 270 normal
individuals collected by the International HapMap Consor-
tium (2003). Third, we introduced PCR-amplified genomic
DNA from each case into a cloning vector and sequenced
between 50 and 55 individual transformants. In two cases
(T167A and G831E), the observed mutant-to-wild-type
allelic ratio was substantially different from 1 (0.19 and
3.2, respectively), suggesting that these alleles did not
represent heterozygous SNPs. In the remaining two cases
(V194M and Y364H), the number of recombinant clones
carrying the mutant allele was similar to that of clones har-
boring the WT sequence (24 versus 27 and 31 versus 21,
respectively), a finding compatible with either a somatic
mutation that was present in most of the cells from which
the original DNA sample was derived or with a heterozy-
gous germline variant.
For comparison with our functional analyses, we also
predicted the effects of all nine candidate mutations in sil-
ico using the SIFT (http://blocks.fhcrc.org/sift/SIFT.html)
and PMut (http://mmb2.pcb.ub.es:8080/PMut) software
programs (Table S2). Three sequence variants (S451F,
G831E, and R834Q) were predicted to affect the function
of FLT3, whereas four changes (T167A, V194M, Y364H,
and M737I) were predicted to be tolerated. The remaining
two mutations (Y572C and V592G) had conflicting results
between the SIFT and PMut algorithms. These findings
illustrate that bioinformatics approaches and functional
assays provide complementary information as to the
potential impact of mutations identified in large-scale
genomic screens.
Ortholog alignments for all nonsynonymous sequence
variants identified in this study, as well as relevant
sequence alignments of all five class III receptor TKs
(PDGFRA, PDGFRB, KIT, CSF1R, and FLT3) and other
TKs with a known role in cancer (EGFR, ERBB2, RET,
MET, and ABL1), are shown in Figure S2. Clinical charac-
teristics of the patients with activating FLT3 mutations are
given in Tables S3 and S4.504 Cancer Cell 12, 501–513, December 2007 ª2007 Elsevier IFLT3 S451F, Y572C, V592G, and R834Q
Differentially Activate Downstream
Signaling Pathways
To examine the signal transduction properties of the four
activating mutations, BaF3 cells expressing FLT3 S451F,
Y572C, V592G, or R834Q were deprived of IL-3 and
then analyzed by western blotting for phosphorylation of
signaling proteins (Figure 2 and Table 2).
Expression of the JM domain mutations Y572C and
V592G resulted in constitutive phosphorylation of ERK1/2,
AKT, STAT3, and STAT5. We recently identified Y589 and
Y591 as sites in the JM domain that are necessary for ab-
errant activation of STAT5 in cells expressing a FLT3 ITD
mutation (Rocnik et al., 2006). To investigate whether
these residues are also required for signal transduction
mediated by JM domain point mutations, we generated
Y589/591F double substitutions in the cDNAs encoding
FLT3 Y572C and V592G. Coexpression of Y589/591F de-
layed the induction of IL-3-independent growth in BaF3
cells (Figure S3A), decreased the proliferation rate of
BaF3 cells in the absence of IL-3 (Figure S3B), and altered
the signaling properties of the two alleles (Figure S3C). The
Figure 2. Differential Activation of Signal Transduction Path-
ways by FLT3 S451F, Y572C, V592G, and R834Q
Expression of FLT3 S451F, Y572C, V592G, and R834Q in BaF3 cells
resulted in constitutive phosphorylation of varying signaling proteins.
Cells were maintained in IL-3-free medium for 6 hr, and whole-cell ly-
sates or immunoprecipitates from whole-cell lysates were analyzed by
western blotting as indicated. The signaling characteristics of the four
mutations were compared with those of FLT3 D835Y and the FLT3 ITD
mutation W51. Cells expressing WT FLT3 or the nontransforming
G831E allele were used as negative controls. Expression of FLT3 in
the different stable cell lines was confirmed by reprobing the blot dem-
onstrating constitutive phosphorylation of AKT with an anti-FLT3 anti-
body.nc.
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phorylation of ERK1/2, STAT3, and STAT5 and attenuated
aberrant activation of AKT. These results, along with our
analysis of the FLT3 structure (see below), support the hy-
pothesis that point mutations in the JM domain, like FLT3
ITD mutations, can alter the conformation of the JM do-
main, potentially resulting in exposure of occult docking
sites such as Y589 and Y591, in turn enabling recruitment
and activation of specific downstream signaling proteins.
The signaling properties of the R834Q substitution were
compared to those of the most frequent AL mutation,
D835Y. Consistent with previous reports (Choudhary
et al., 2005; Grundler et al., 2005; Rocnik et al., 2006),
BaF3 cells expressing D835Y showed constitutive activa-
tion of ERK1/2 and AKT, but not STAT5. Furthermore, we
found that expression of D835Y was associated with con-
stitutive phosphorylation of STAT3. The R834Q mutation,
on the other hand, resulted in phosphorylation of ERK1/2
but not AKT, STAT3, or STAT5. This signaling pattern was
associated with increased sensitivity to growth inhibition
Table 2. Constitutive Phosphorylation of Signaling
Molecules in BaF3 Cells Expressing Activating FLT3
Mutations
FLT3 Mutation
Signaling
molecule
S451F Y572C V592G R834Q D835Y W51
FLT3 + + + + + +
STAT5  + +   +
ERK1/2 + + + + + +
AKT  + +  + 
STAT3  + +  + 
S451F, Y572C, V592G, and R834Q were identified in this
study; D835Y and W51 are known activating FLT3 mutations
that have been described previously. +, constitutive phos-
phorylation; , no constitutive phosphorylation.Canby the MEK inhibitor PD98059 as compared to cells har-
boring the D835Y mutation (Figures 3A and 3B), indicating
a higher relative contribution of ERK signaling to the trans-
forming activity of the R834Q allele. Similar to R834Q-
positive cells, cells expressing the S451F mutation also
showed constitutive phosphorylation of ERK1/2, but no
induction of AKT, STAT3, or STAT5. These results suggest
that activation of the MAPK pathway in the absence of
PI3K/AKT, STAT3, or STAT5 signaling is sufficient for
transformation of hematopoietic cells by specific FLT3 al-
leles and that cells carrying different FLT3 mutations are
differentially dependent on signaling mechanisms that
involve the MEK/ERK cascade.
FLT3 S451F, Y572C, V592G, and R834Q Confer
Varying Sensitivity to the TK Inhibitor PKC412
To determine the sensitivity of the four activating muta-
tions to FLT3 inhibition, BaF3 cells expressing FLT3
S451F, Y572C, V592G, or R834Q were treated with in-
creasing concentrations of the small-molecule TK inhibitor
PKC412. FLT3 Y572C, V592G, and R834Q conferred high
sensitivity to PKC412 (inhibitory concentration of 50%
[IC50], 2.5 nM, 5 nM, and 2.3 nM, respectively), whereas
a considerably higher IC50 (48 nM) was observed for
FLT3 S451F (Figure 4A). Western blot analysis showed
that treatment with PKC412 led to dose-dependent
decreases in FLT3 autophosphorylation and in phosphor-
ylation of ERK1/2 that correlated with inhibition of cell
growth (Figure 4B). WT FLT3-expressing BaF3 cells grown
in the presence of IL-3 were used as a control for toxicity
unrelated to FLT3 inhibition, and no antiproliferative effect
was observed for concentrations of PKC412 up to 50 nM
(Figure 4A). These data show that the four activating FLT3
mutations identified in our mutation screen can be
inhibited by PKC412 and that Y572C, V592G, and
R834Q are considerably more sensitive to this compound
than S451F.Figure 3. Varying Sensitivity of Different
FLT3 AL Mutations to MEK Inhibition
(A) Expression of FLT3 R834Q was associated
with a higher sensitivity to MEK inhibition as
compared to FLT3 D835Y. BaF3 cells stably
expressing FLT3 R834Q or D835Y and growing
in the absence of IL-3 were treated with
PD98059 as indicated. Cell viability was mea-
sured after 48 hr, and the proportion of viable
cells relative to the control (no inhibitor) was
plotted. IC50 values are indicated. Experiments
were performed in triplicate. Values are repre-
sented as mean ± SEM.
(B) PD98059 treatment of BaF3 cells express-
ing FLT3 R834Q or D835Y resulted in dose-de-
pendent inhibition of ERK1/2 phosphorylation.
Cells were incubated with varying drug con-
centrations for 15 min, and whole-cell lysates
were analyzed by western blotting as indi-
cated.cer Cell 12, 501–513, December 2007 ª2007 Elsevier Inc. 505
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Driver and Passenger Mutations of FLT3 in AMLFigure 4. Varying Sensitivity of FLT3 S451F, Y572C, V592G, and R834Q to Kinase Inhibition by PKC412
(A) Expression of FLT3 Y572C, V592G, or R834Q was associated with higher sensitivity to FLT3 inhibition as compared to FLT3 S451F. BaF3 cells
growing in the absence of IL-3 were treated with PKC412 as indicated. Cell viability was measured after 48 hr, and the proportion of viable cells relative
to the control (no inhibitor) was plotted. IC50 values are indicated. Experiments were performed in triplicate. Values are represented as mean ± SEM.
(B) PKC412 treatment of BaF3 cells expressing FLT3 S451F, Y572C, V592G, and R834Q resulted in dose-dependent decreases in FLT3 and ERK1/2
phosphorylation. Cells were incubated with varying drug concentrations for 2 hr, and whole-cell lysates were analyzed by western blotting as
indicated.Mutation of FLT3 V592 Promotes Aberrant
Signal Transduction and Proliferation
of Human AML Cells
To investigate the role of mutant FLT3 in human AML cells,
we analyzed the MONO-MAC-6 cell line that has been
reported to contain a V592A substitution in the FLT3 JM
domain (Spiekermann et al., 2003). DNA sequence analy-
sis confirmed the presence of a homozygous V592A
mutation in this cell line (data not shown). Lentiviral trans-
duction of MONO-MAC-6 cells with two short hairpin RNA
(shRNA) constructs targeting different regions of the FLT3
transcript resulted in stable downregulation of FLT3
mRNA (Figure 5B) and reduced levels of FLT3 protein
(Figure 5C). Knockdown of FLT3 was associated with
a substantial reduction in cell viability as compared to cells
transduced with a nontargeting control shRNA (Figure 5A).
Western blot analysis showed that suppression of FLT3
resulted in loss of STAT5 phosphorylation (Figure 5C),
indicating that STAT5 is a downstream target of mutations
involving FLT3 V592, consistent with our signaling studies
in BaF3 cells. These results suggest that endogenous
point mutations of FLT3 V592 promote the growth and
survival of human AML cells and that this effect is medi-
ated through aberrant STAT5 activation.
Structural Analysis of FLT3 Mutations
Based on the crystal structure of the intracellular domains
of FLT3 (Protein Data Bank accession code 1RJB;
Figure 6A), we assessed the potential mechanism by which
point mutations in the JM domain and in the AL result in
constitutive FLT3 kinase activity. Residues Y572 and506 Cancer Cell 12, 501–513, December 2007 ª2007 Elsevier IR834 seem to be involved in maintaining the energetic
favorability of the autoinhibited conformation of FLT3.
Loss of the stabilizing effects of these residues should
favor the active conformation. Y572, which has thus far
not been found mutated in AML, is described as the first
amino-terminal residue visible in the electron density of
the crystal structure (Griffith et al., 2004). It is a key
‘‘hook’’ for the JM domain and is critical to maintain the
autoinhibited conformation of FLT3 (Figure 6B). The
Y572C substitution is expected to result in a substantial
loss of hydrogen bonding networks and extensive hydro-
phobic interactions, with a consequent reduction in the
energetic favorability of this conformation. Likewise, loss
of hydrogen bonding networks that would result from the
R834Q and D835Y mutations is expected to destabilize
the autoinhibited kinase conformation (Figures 6C and 6D).
Conversely, structural analysis suggests that the non-
transforming G831E substitution may not deleteriously
affect the stability of the autoinhibited conformation. The
molecular surface of autoinhibited FLT3 shows that there
is a cavity directly adjacent to G831. This cavity is filled
with water molecules and falls between the autoinhi-
bited-conformation AL and JM domain (Figure 6E). Even
though mutation of this glycine residue to glutamic acid
is a substantial change, the glutamic acid residue should
be able to be accommodated in the autoinhibited confor-
mation by displacement of a number of water molecules.
G831 lies within the invariant protein kinase DFG motif
required for correct Mg2+ATP coordination (Karlsson
et al., 1993) and is important for conformational move-
ments of the DFG motif between active and inactive statesnc.
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Human AML Cells
(A) Downregulation of FLT3 using shRNA
constructs TRCN 772 and TRCN 773 inhibited
the growth of a human AML cell line, MONO-
MAC-6, that harbors a homozyogus V592A
mutation in the FLT3 JM domain. Experiments
were performed in triplicate. Values are repre-
sented as mean ± SEM.
(B) Transduction of MONO-MAC-6 cells with
shRNA constructs TRCN 772 and TRCN 773
resulted in decreased FLT3 mRNA levels as
compared to a nontargeting control construct.
Experiments were performed in duplicate.
Values are represented as mean ± SEM.
(C) Suppression of FLT3 mRNA was associ-
ated with a reduction in FLT3 protein (upper
panels) and with loss of STAT5 phosphoryla-
tion (lower panels).(Levinson et al., 2006). Consequently, the G831E mutation
may stabilize FLT3 in the autoinhibited conformation and
result in reduced kinase activity, consistent with our data
showing a lack of FLT3 autophosphorylation in cells
expressing FLT3 G831E.
DISCUSSION
We have used high-throughput DNA sequence analysis to
determine the frequency and spectrum of mutations in the
FLT3 gene in adult AML patients without known FLT3 ITDs
or AL mutations. Sequencing of all FLT3 coding exons
identified nine candidate leukemogenic alleles in six exons
corresponding to different domains of the FLT3 receptor.
Large-scale mutational profiling studies in cancer typi-
cally result in extensive lists of validated nonsynonymous
sequence variants. A major challenge of these studies is to
distinguish driver mutations that are responsible for malig-
nant transformation from nonfunctional passenger alter-
ations that arise in the malignant clone by chance andCanaccumulate during repeated rounds of cell division. To
identify genetic changes with a role in tumorigenesis, sta-
tistical models have been developed that incorporate
mutational frequency and distribution, and it has been
inferred from such approaches that nonsynonymous pas-
senger mutations are present at a higher frequency than
previously anticipated (Greenman et al., 2007; Sjoblom
et al., 2006; Wood et al., 2007). We provide functional doc-
umentation of this concept by using a different strategy
that combined both high-throughput DNA sequence anal-
ysis of FLT3 in primary AML samples with experimental
validation of all potential driver mutations identified. Cyto-
kine independence assays and biochemical analysis
revealed that of the 9 candidate leukemogenic alleles, 4
are gain-of-function mutations that result in constitutive
kinase activation and stimulation of downstream signaling
pathways, properties that are relevant to leukemogenesis
and can be exploited therapeutically, whereas the remain-
ing 5 alleles were not associated with increased kinase
activity and aberrant signal transduction.cer Cell 12, 501–513, December 2007 ª2007 Elsevier Inc. 507
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Mutations
(A) Ribbon representation of the crystal struc-
ture of the FLT3 kinase domain (Protein Data
Bank, accession code 1RJB). The structure is
a typical kinase fold crystallized in the autoinhi-
bited conformation with the JM domain pack-
ing closely to the kinase domain and locking
the protein in this conformation.
(B) Hydrogen bonding network formed by FLT3
Y572. Y572 inserts into the catalytic cleft of
FLT3, where the phenolic hydroxyl oxygen
forms hydrogen bonds to the catalytic glutamic
acid, E661, and an ordered water molecule.
The aromatic ring also makes extensive hydro-
phobic contacts. The Y572C mutation will dis-
rupt this ‘‘hook’’ that locks the JM domain in
the autoinhibited conformation.
(C) Hydrogen bonding network formed by FLT3
R834. R834 is critical to the formation of a
hydrogen bonding network that incorporates
interactions with the side chains of residues
N816, R815, Y842, D811, the backbone car-
bonyl oxygen of R815, and two water mole-
cules. This network is directly adjacent to a
hydrogen bonding network in which N841
plays a critical role.
(D) Hydrogen bonding network formed by FLT3
D835. D835 is an integral part of a hydrogen
bonding network that seems to stabilize the AL backbone in the autoinhibited conformation. There is a hydrogen bond directly between the carboxyl
group and the backbone amide of residue S836. There is also an indirect hydrogen bond between the caryboxyl group and the backbone amide of
M837 mediated by a water molecule.
(E) Surface representation of the region proximal to G831. The molecular surface of FLT3 protein atoms is shown as a transparent gray surface. The
surface is colored green where it contacts G831, and water molecules are shown as red spheres. The G831E mutation may not disrupt this confor-
mation due to the proximity of a water-filled cavity adjacent to G831. In this figure, amino acid residues are shown in stick representation with nitrogen
atoms in blue, oxygen in red, and carbon atoms the same color as the corresponding domain. Water molecules are shown as red spheres and
hydrogen bonds as dashed red lines with their lengths labeled in A˚. This figure was made using the program PyMOL (www.pymol.org).These results also indicate that functional analyses can
provide information beyond that derived from statistical
methods for identifying driver mutations. First, we show
that rare sequence variants occurring at frequencies that
would not allow them to be distinguished from unselected
passenger changes can be drivers. Second, we report
that alleles in the kinase domain and in the AL—highly
conserved and functionally relevant domains that, based
on mathematical approaches, are likely to harbor driver
mutations—may not be associated with a detectable
gain of function. Third, statistical techniques result in iden-
tification of candidate cancer genes, but do not predict the
ability of individual alleles to contribute to transformation.
Our analysis of a series of nonsynonymous sequence var-
iants in FLT3, a validated cancer gene (Futreal et al., 2004),
indicates that functional studies are needed to comple-
ment the bioinformatic approaches that have been de-
scribed to date.
In addition to mutational frequency and distribution,
statistical methods for assessing the functional relevance
of DNA sequence variants in cancer rely on discerning ac-
quired mutations from inherited polymorphisms. While the
analysis of germline DNA is essential to assess the origin
of cancer-associated genomic alterations and to deter-
mine whether a mutation has been selected for during508 Cancer Cell 12, 501–513, December 2007 ª2007 Elsevier Itumorigenesis, previous findings in solid tumors indicate
that the presence of a kinase mutation in constitutional
DNA does not exclude the possibility that it has a potential
role in malignant transformation (Bell et al., 2005; Jeffers
et al., 1997; Mulloy et al., 2007; Plaza-Menacho et al.,
2006). These data further support the conclusion that
the interpretation of high-throughput sequencing studies
can be improved through functional assessment of candi-
date oncogenic alleles.
The four activating mutations that were identified in
our screen are located in the EC domain (S451F), the
JM domain (Y572C and V592G), and the AL (R834Q)
of FLT3. Sequence variants in the EC region (D324N
and N520Y) have been described previously in patients
with AML (Ley et al., 2003; Syampurnawati et al., 2007).
However, D324N is also present in normal individuals
and in nonhematopoietic tissues from AML patients
and does not confer cytokine-independent growth to
BaF3 cells (Schnittger et al., 2006), whereas the func-
tional consequences of N520Y have not been assessed.
Our results thus document that FLT3, like EGFR and
KIT (Gari et al., 1999; Lee et al., 2006), can be activated
by mutations in the EC domain. To determine the
mechanism by which the S451F mutation results in
constitutive FLT3 kinase activity, structural analysis ofnc.
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be required.
Point mutations in the region between amino acids 579
and 594 in the FLT3 JM domain have been detected in
a small proportion of AML cases (Reindl et al., 2006; Stir-
ewalt et al., 2004). We have found a valine to glycine
substitution involving residue 592 and a mutation involving
Y572. Y572 is the first amino acid of the JM domain, and
analysis of the crystal structure of the FLT3 cytoplasmic
domain has suggested a key role for this residue in kinase
autoinhibition (Griffith et al., 2004). Our structural analysis
suggests that mutation of Y572 would result in disruption
of its extensive interactions with the surrounding FLT3
subdomains and consequent destabilization of the inac-
tive kinase conformation. In support of this hypothesis,
the Y572C substitution that was identified in our mutation
screen results in constitutive FLT3 kinase activity. These
data provide genetic evidence for the importance of
Y572 in maintaining the autoinhibited conformation of
FLT3 and suggest that any mutation that interferes with
the stability of the JM domain in this conformation is likely
to be transforming.
The signaling properties of the two JM domain point
mutations are similar to those of FLT3 ITDs (Parcells
et al., 2006). In particular, aberrant activation of STAT5
by JM domain point mutations appears to involve two tyro-
sine residues, Y589 and Y591, that are essential for FLT3
ITD-mediated induction of STAT5 and leukemic transfor-
mation in vivo (Rocnik et al., 2006). Analysis of the role of
Y589 and Y591 also provided insights into the deregulation
of other signaling pathways by mutant FLT3. For example,
the majority of primary AML samples are characterized by
activated MAPK and PI3K/AKT signaling; however, the
fact that dysregulation of various upstream effectors can
result in aberrant phosphorylation of ERK1/2 and AKT indi-
cates that the MAPK and PI3K/AKT cascades may be ac-
tivated through a variety of different mechanisms (Martelli
et al., 2006; Platanias, 2003). In support of the hypothesis
that mutant TKs activate downstream signaling pathways
by distinct mechanisms, phosphorylation of ERK1/2 and
AKT by FLT3 JM domain point mutations also requires
Y589 and Y591, and similar observations were made for
constitutive activation of STAT3. These results suggest
that the different types of JM domain mutations (ITDs
and point mutations) contribute in similar ways to myeloid
leukemogenesis and demonstrate that Y589 and Y591 are
critical for the induction of several signaling pathways that
are activated in leukemias with FLT3 JM domain muta-
tions. Furthermore, these findings illustrate the potential
of point mutations to alter the substrate specificity of
protein kinases. Whether FLT3 Y589/591-mediated signal
transduction in AML involves direct engagement of down-
stream effectors by these residues or requires additional
adaptor molecules is currently unknown.
Previously described mutations in the FLT3 AL include
substitutions, insertions, or deletions within a region be-
tween amino acids 834 and 842, with D835 being the
most commonly affected residue (Frohling et al., 2005).
We identified nonsynonymous substitutions at codonsCa831 and 834. Analysis of the crystal structure of the
FLT3 kinase domain suggests that mutation of residue
R834 would interfere with the stability of the autoinhibited
conformation, and in agreement with this hypothesis,
FLT3 R834Q has constitutive kinase activity and confers
IL-3-independent growth to BaF3 cells. In contrast, muta-
tion of the conserved DFG motif G831 to glutamic acid
may deleteriously affect the structural requirements for
enzymatic activity, is expected to be compatible with the
autoinhibited conformation, and does not result in trans-
formation of hematopoietic cells. These results illustrate
the value of structural analysis for understanding the
atomic-level mechanisms by which TK mutations associ-
ated with human leukemias function. In addition, these
data indicate that the autoinhibited conformation of FLT3
is critically dependent on the stabilizing contacts of a lim-
ited number of specific amino acids, whereas mutation of
other residues within the AL does not alter the structure
and function of the FLT3 kinase.
Analysis of the signaling properties of FLT3 R834Q
demonstrated that this mutation, unlike the more common
D835Y allele, results in activation of ERK1/2, but not AKT,
STAT3, or STAT5. Consistent with this observation, the
R834Q mutation is associated with enhanced sensitivity
to MEK inhibition, indicating that cells expressing R834Q
are more reliant on MAPK signaling than are D835Y-
expressing cells that constitutively phosphorylate multiple
signaling proteins. These results suggest that there are
not only differences in signal transduction between vari-
ous FLT3 mutation classes, for example, ITDs and AL
mutations (Choudhary et al., 2005; Grundler et al., 2005),
but also between distinct alleles within a given mutation
class and that cells carrying different FLT3 mutations are
differentially dependent on certain signaling pathways.
To determine the functional consequences of candidate
mutations, we used an in vitro assay that is based on
exogenous expression of mutated alleles in murine hema-
topoietic cells. This assay has proved to be of value for the
assessment of increased TK activity and perturbed signal
transduction and has been validated for numerous TK
alleles identified in human hematologic malignancies,
including FLT3 ITDs and AL mutations (Clark et al., 2004;
Weisberg et al., 2002), as well as for TK alleles associated
with solid tumors, such as mutations in the EGFR kinase
domain and the recently discovered EML4-ALK fusion in
patients with non-small-cell lung cancer (Jiang et al.,
2005; Soda et al., 2007). On the other hand, conversion
of BaF3 cells to cytokine independence may not faithfully
assess the functional implications of certain mutations,
either because they require expression of additional pro-
teins (Lu et al., 2005) or because cooperativity between
two or more mutations is required for signaling pathway
activation. Lastly, this assay may fail to detect a gain of
function conferred by kinase mutations that do not result
in increased enzymatic activity. For instance, Wan et al.
(2004) described three mutants of the serine-threonine
kinase BRAF with impaired catalytic activity that are
capable of stimulating downstream signaling through
transactivation of CRAF. Although we observed noncer Cell 12, 501–513, December 2007 ª2007 Elsevier Inc. 509
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pressing FLT3 mutations that read out as nonfunctional
in the BaF3 assay, it is possible that some of these alleles
stimulate other effector molecules that were not analyzed
in our study. We recognize that it is impossible to defini-
tively exclude any conceivable function of a given muta-
tion. Nonetheless, the nontransforming mutations identi-
fied in our screen do not meet conventional criteria for
effects on kinase activation.
The activating mutations identified in our study con-
ferred varying degrees of sensitivity to the small-molecule
TK inhibitor PKC412. Cells expressing Y572C, V592G, or
R834Q were highly sensitive to this compound, as has
been reported for other JM domain (Reindl et al., 2006)
and AL mutations (Choudhary et al., 2005; Grundler
et al., 2003; Weisberg et al., 2002). In contrast, cytotoxic
responses in S451F-expressing cells required substan-
tially higher drug concentrations. The determinants of
response to pharmacologic inhibition of FLT3 are diverse
and remain only partly understood. In general, the pres-
ence of mutant FLT3 is associated with increased drug
sensitivity (DeAngelo et al., 2006; Fiedler et al., 2005),
yet there appears to be substantial variation among the
different mutation types (Choudhary et al., 2005; Grundler
et al., 2003; Weisberg et al., 2002) as well as between
individual alleles within the same mutation class (Clark
et al., 2004; Grundler et al., 2003). In addition, it has
been observed that patients without FLT3 ITDs or any of
the known AL mutations may also derive benefit from
FLT3 inhibitor therapy, which might be related to the pres-
ence of previously unrecognized mutations (Schittenhelm
et al., 2006), and in vitro studies in primary AML samples
have shown that there is substantial interpatient variation
in the degree of dependency on FLT3 signaling (Knapper
et al., 2006). Our findings further illustrate the complex
relationship between FLT3 mutation status and response
to pharmacologic FLT3 inhibition.
In summary, our results demonstrate that previously un-
recognized activating FLT3 mutations in the EC domain,
the JM domain, and the AL occur in patients with AML, al-
beit at a low frequency. Since mutations lying outside the
usually studied mutational hotspots may confer sensitivity
to small-molecule TK inhibitors, eligibility for clinical trials
of FLT3-targeted therapies should not be based on diag-
nostic screens that are limited to the detection of only
a fraction of the FLT3 mutations associated with AML.
The development of sensitive, allele-specific assays,
such as mass spectrometry-based genotyping (Thomas
et al., 2007), will allow all patients enrolled on trials of
FLT3 inhibitors to be genotyped for all known FLT3 alleles,
and it is hoped that similar strategies will be used in trials
of molecularly targeted therapies for patients with different
hematopoietic malignancies and solid tumors.
FLT3 is a highly annotated and well-studied cancer
gene known to play a key role in myeloid leukemogenesis.
The finding that only a fraction of the nonsynonymous
FLT3 mutations associated with AML result in constitutive
kinase activity illustrates the challenge in distinguishing
between sequence variants that contribute to malignant510 Cancer Cell 12, 501–513, December 2007 ª2007 Elseviertransformation and nonfunctional passenger mutations.
Given that the increasing throughput of DNA sequencing
technologies will allow improved characterization of
somatic cancer genomes, these data demonstrate that
a combination of genetic and functional approaches will
be crucial in order to identify the mutations that truly drive
the development of cancer and to validate the potential of
suspected oncogenic alleles as therapeutic targets.
EXPERIMENTAL PROCEDURES
Patient Samples
This study included 349 adult patients with AML, de novo or secondary
after treatment for a primary malignancy or following myelodysplasia,
as defined by French-American-British Cooperative Group criteria or
the World Health Organization classification (Bennett et al., 1985;
Harris et al., 1999). Diagnostic BM and peripheral blood samples
were collected after obtaining informed consent according to the Dec-
laration of Helsinki and with institutional review board approval of the
relevant institutions. All samples were enriched for mononuclear cells
by density centrifugation before banking. Only samples with more than
50% blasts were included for DNA sequence analysis, and more than
80% of the samples had at least 80% blasts. All specimens that were
analyzed by DNA sequencing were negative for FLT3 ITDs, as
assessed by PCR amplification of exons 14 and 15; for FLT3 AL muta-
tions involving codons 835 and 836, as assessed by PCR amplification
of exon 20 followed by EcoRV digestion; for activating KIT mutations,
as assessed by sequencing of exons 8 and 17; and for mutations
involving NRAS codons 12, 13, and 61, as assessed by sequencing
of exons 1 and 2.
FLT3 Mutational Analysis and Selection of Candidate
Mutations
Extraction of genomic DNA, amplification of FLT3 exons, bidirectional
sequencing, and sequence detection were performed using a high-
throughput resequencing approach as previously described (Levine
et al., 2005). External gene-specific primers and internal M13-
appended primers are listed in Table S5. Analysis of sequence traces
was performed using Mutation Surveyor version 2.28 (SoftGenetics,
State College, PA). Five steps were used to identify mutations of inter-
est. First, any synonymous substitutions were not analyzed further.
Second, known SNPs were excluded by comparison to the dbSNP
database (release 127; http://www.ncbi.nlm.nih.gov/projects/SNP).
Third, published data sets (Greenman et al., 2007; Ley et al., 2003)
were queried to exclude any nonsynonymous substitutions in the
FLT3 coding sequence that have been detected in DNA samples
derived from normal tissues. Fourth, sequence chromatograms were
visually inspected to remove false positive calls in the automated anal-
ysis. Fifth, candidate mutations were reamplified and sequenced from
the original DNA sample for independent verification. Leukemic cells at
diagnosis and a matched remission sample were analyzed in one case
with a presumptive leukemogenic mutation in the FLT3 kinase domain,
M737I.
Genotyping
Mass spectrometry genotyping was performed as previously
described (Levine et al., 2005). Primers and primer extension probes
for detection of the different FLT3 alleles are listed in Table S6.
DNA Constructs and Retrovirus Production
Sequence variants were introduced into the full-length FLT3 cDNA
using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA). All mutations were confirmed by sequencing of the entire
FLT3 open reading frame. The mutant cDNAs were cloned into the
MSCV-PGK-neo retroviral vector, and full-length protein expression
was documented by western blotting. Generation of retroviralInc.
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previously (Rocnik et al., 2006). BaF3 cells transduced with MSCV-
PGK-neo constructs were selected with G418 in the presence of IL-3
for 14 days.
Cell Culture
BaF3 cells were maintained in RPMI-1640 supplemented with 10% fe-
tal calf serum and 10% WEHI-conditioned medium as a source of IL-3.
For cytokine independence assays, cells transduced with each of the
MSCV-PGK-neo retroviral contructs were seeded at a density of
0.33 3 106/ml in IL-3-free medium, and the number of viable cells
was determined daily by trypan blue exclusion. For growth inhibition
assays, cells were seeded at a density of 1 3 105/ml in IL-3-free
medium with various concentrations of PKC412 (Novartis, Basel, Swit-
zerland) or PD98059 (Calbiochem, San Diego, CA), and the number of
viable cells was determined after 48 hr using the CellTiter 96AQueous
One Solution Proliferation Assay (Promega, Madison, WI).
Immunoprecipitation and Western Blotting
Immunoprecipitation and western blotting were performed as de-
scribed previously (Rocnik et al., 2006) using the following antibodies:
anti-FLT3, anti-STAT5, anti-phospho-ERK1/2 (T202/Y204) (Santa Cruz
Biotechnology, Santa Cruz, CA); anti-STAT3, anti-phospho-STAT3
(Y705), anti-phospho-STAT5 (Y694), anti-ERK1/2, anti-AKT, anti-
phospho-AKT (S473) (Cell Signaling Technology, Beverly, MA); and
anti-phosphotyrosine (4G10) (Upstate, Lake Placid, NY).
Knockdown of FLT3 Expression
Two pLKO.1-based lentiviral vectors encoding shRNAs targeted to the
30 untranslated region (TRCN 772) or the coding sequence (TRCN 773)
of the human FLT3 mRNA, and a pLKO.1 construct containing a non-
targeting shRNA sequence were obtained from the MISSION TRC-Hs
1.0 (Human) shRNA library (Root et al., 2006). The oligonucleotide
sequences of the shRNAs were as follows (21-nucleotide stem
sequences matching the target transcript underlined; noncomplemen-
tary 6-nucleotide loop sequences italicized): TRCN 772, 50-CCG GCG
TCT GCG TTT ACT CTT GTT TCT CGA GAA ACA AGA GTA AAC GCA
GAC GTT TTT-30; TRCN 773, 50-CCG GGC TAA CTT CTA CAA ACT
GAT TCT CGA GAA TCA GTT TGT AGA AGT TAG CTT TTT-30. Gener-
ation of lentiviral supernatants and infection of human AML cells were
performed as described previously (Scholl et al., 2007).
Analysis of the FLT3 Structure
The crystal structure of the kinase domain of FLT3 was downloaded
from the Protein Data Bank (http://www.pdb.org; accession code
1RJB) and analyzed in O (Jones et al., 1991).
Supplemental Data
The Supplemental Data include three supplemental figures and six
supplemental tables and can be found with this article online at
http://www.cancercell.org/cgi/content/full/12/6/501/DC1/.
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